Key terms

About IKT

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IKT news

Apr 03 8:26am ET Inhibikase Therapeutics announces pre-IND meeting with FDA for IkT-001Pro by TipRanks Apr 02 3:15pm ET Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress by TipRanks Mar 07 8:38am ET Inhibikase Therapeutics to provide trial update for Risvodetinib by TipRanks Mar 05 10:45am ET Buy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s Pipeline by TipRanks Mar 01 10:55am ET Inhibikase Therapeutics’ IkT-001Pro: A Promising Buy Amidst FDA Progress and Expanded Market Potential by TipRanks Feb 28 4:57pm ET Inhibikase Therapeutics announces outcomes of pre-NDA meeting with FDA by TipRanks Feb 21 8:36am ET Inhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial Standing by TipRanks Feb 08 4:11am ET Inhibikase Discusses FDA Pathway for New Cancer Drug by TipRanks Feb 07 8:03am ET Inhibikase Therapeutics announces outcomes of pre-NDA meeting with FDA by TipRanks Jan 16 4:10pm ET Inhibikase Therapeutics CFO Frattaroli to retire at Q1-end, Lees-Rolfe succeeds by TipRanks

No recent press releases are available for IKT

IKT Financials

1-year income & revenue

Key terms

IKT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IKT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching